Orphans and babies as young as three months old have been used as guinea pigs in potentially dangerous medical experiments sponsored by a giant pharmaceutical company.
British giant GlaxoSmithKline is embroiled in the scandal.
The firm sponsored experiments on the children from Incarnation Children's Center, a New York care home that specializes in treating HIV sufferers and is run by Catholic charities.
The children had either been infected with HIV or born to HIV-positive mothers.
Their parents were dead, untraceable or deemed unfit to look after them.
According to documents, Glaxo has sponsored at least four medical trials since 1995 using Hispanic and black children at Incarnation.
The documents give details of all clinical trials in the US and reveal that the experiments sponsored by Glaxo were designed to test the "safety and tolerance" of AIDS medications, some of which have potentially dangerous side effects.
Glaxo manufactures a number of drugs designed to treat HIV, including AZT.
Normally, trials on children would require parental consent but, as the infants are in care, New York's authorities hold that role.
The city health department has launched an investigation into claims that more than 100 children at Incarnation were used in 36 experiments -- at least four of them co-sponsored by Glaxo.
Some of these trials were designed to test the "toxicity" of AIDS medications.
One involved giving children as young as 4 years old a high-dosage cocktail of seven drugs at one time.
Another looked at the reaction in six-month-old babies to a double dose of measles vaccine.
Most experiments were funded by federal agencies like the National Institute of Allergy and Infectious Diseases.
Until now Glaxo's role had not emerged.
In 1997 an experiment co-sponsored by Glaxo used children from Incarnation to "obtain tolerance, safety and pharmacokinetic" data for herpes drugs.
In a more recent experiment, the children were used to test the drug AZT.
A third experiment sponsored by Glaxo and US drug firm Pfizer investigated the "long-term safety" of anti-bacterial drugs on three-month-old babies.
The medical establishment has defended the trials, arguing they enabled these children to obtain state-of-the-art therapy that they would otherwise not have received for illnesses that could potentially be fatal.
However, health campaigners argue there is a difference between providing the latest drugs and experimentation.
They claim many of the experiments were "phase 1 trials" -- among the most risky.
They also claim that HIV tests for babies are not a reliable indicator of actual infection and therefore toxic drugs could have been given to healthy infants. HIV drugs are similar to those used in chemotherapy and can have serious side effects.
Vera Sharav, president of the Alliance for Human Research Protection, said the children had been treated like "laboratory animals."
"These are some of the most vulnerable individuals in the country and there appears to be a policy of giving drug firms access to them," she said.
"Throughout the history of medical research we have seen prisoners abused, the mentally ill abused and now poor kids in a care home," she said.
Sharav has urged the US Food and Drug Administration to investigate and has demanded complete disclosure of all adverse effects suffered by the children, including deaths.
Glaxo has confirmed it provided funds for some of the experiments but denied any improper action.
A spokeswoman said, "These studies were implemented by the US AIDS Clinical Trial Group, a clinical research network paid for by the National Institutes of Health.
"Glaxo's involvement in such studies would have been to provide study drugs or funding but we would have no interactions with the patients.
"Generally speaking, clinical research is carefully regulated in the US and it would be the responsibility of the appropriate authorities to ensure all subjects in a clinical trial provided appropriate, informed consent to conform with all local laws and regulations regarding legal authority in the case of minors."
The Incarnation trials were run by Columbia University Medical Center doctors.
Columbia spokeswoman Annie Bayne said there had been no clinical trials at Incarnation since 2000 and that consent for the children was provided by the Administration for Children's Services, which relies on a panel of doctors and lawyers to determine whether the benefits of a trial for each child outweighs the risks to the child.
"There are many safeguards in the system. HIV is eventually a fatal disease, but drug therapy has lengthened life significantly," Bayne said.
A spokesman for Incarnation said regarding the scandal, "The purpose of the trials was to test the efficacy of HIV medication."
"These trials were based on scientific evidence of their potential value in the treatment of HIV- infected children," the spokesman said.
STEPPING UP: Diminished US polar science presence mean opportunities for the UK and other countries, although China or Russia might also fill that gap, a researcher said The UK’s flagship polar research vessel is to head to Antarctica next week to help advance dozens of climate change-linked science projects, as Western nations spearhead studies there while the US withdraws. The RRS Sir David Attenborough, a state-of-the-art ship named after the renowned British naturalist, would aid research on everything from “hunting underwater tsunamis” to tracking glacier melt and whale populations. Operated by the British Antarctic Survey (BAS), the country’s polar research institute, the 15,000-tonne icebreaker — boasting a helipad, and various laboratories and gadgetry — is pivotal to the UK’s efforts to assess climate change’s impact there. “The saying goes
FRUSTRATIONS: One in seven youths in China and Indonesia are unemployed, and many in the region are stuck in low-productivity jobs, the World Bank said Young people across Asia are struggling to find good jobs, with many stuck in low-productivity work that the World Bank said could strain social stability as frustrations fuel a global wave of youth-led protests. The bank highlighted a persistent gap between younger and more experienced workers across several Asian economies in a regional economic update released yesterday, noting that one in seven young people in China and Indonesia are unemployed. The share of people now vulnerable to falling into poverty is now larger than the middle class in most countries, it said. “The employment rate is generally high, but the young struggle to
ENERGY SHIFT: A report by Ember suggests it is possible for the world to wean off polluting sources of power, such as coal and gas, even as demand for electricity surges Worldwide solar and wind power generation has outpaced electricity demand this year, and for the first time on record, renewable energies combined generated more power than coal, a new analysis said. Global solar generation grew by a record 31 percent in the first half of the year, while wind generation grew 7.7 percent, according to the report by the energy think tank Ember, which was released after midnight yesterday. Solar and wind generation combined grew by more than 400 terawatt hours, which was more than the increase in overall global demand during the same period, it said. The findings suggest it is
FIRST STAGE: Hamas has agreed to release 48 Israeli hostages in exchange for 250 ‘national security prisoners’ as well as 1,700 Gazans, but has resisted calls to disarm Israel plans to destroy what remains of Hamas’ network of tunnels under Gaza, working with US approval after its hostages are freed, it said yesterday. Israeli Minister of Defense Israel Katz said that the operation would be conducted under an “international mechanism” led by the US. “Israel’s great challenge after the hostage release phase will be the destruction of all Hamas terrorist tunnels in Gaza,” Katz said. “I have ordered the army to prepare to carry out this mission,” he added. Hamas operates a network of tunnels under Gaza, allowing its fighters to operate out of sight of Israeli reconnaissance. Some have passed under
RSS